Biogen Idec Inc (BIIB) 391.66 $BIIB
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:23PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) announced that the company and its partner R-Tech Ueno, Ltd have entered into a stipulation and license agreement with Par Pharmaceutical, Inc.
IPXL: 39.51 (+0.69), LCI: 57.78 (-0.91), BIIB: 391.66 (-0.45), SCMP: 15.32 (+0.04)
Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 11:40AM CST
Oncolytics Biotech Inc.'s (ONCY) lead candidate, Reolysin, has been granted orphan drug designation by the FDA for the treatment of ovarian cancer.
BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), BMRN: 100.76 (+1.98)
Forget Gilead Sciences: Here Are 3 Better Biotech Stocks
Motley Fool Staff - Motley Fool - Thu Feb 12, 7:19AM CST
A doubling of Gilead Sciences ' sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences' sales growth set to slow this year, investors may find that these three top biotech stocks...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.30% Loss
Comtex SmarTrend(R) - Wed Feb 11, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $388.53 to a high of $396.86. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $394.06 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 391.66 (-0.45)
Stocks End Mixed: Molina Healthcare Rises Again
at Investor's Business Daily - Wed Feb 11, 3:22PM CST
Stocks ended mixed Wednesday as investors fretted about talks between Greek and European finance ministers about a debt compromise. The Nasdaq edged up 0.3%, while the S&P 500 and the Dow Jones industrial average each dipped a fraction. Volume was...
BIIB: 391.66 (-0.45), MOH: 59.66 (+0.26), CELG: 115.88 (+0.16), RAD: 8.34 (+0.25)
Biogen Idec: A True Competitor On Sustainability Metrics
Katherine Schrank - at Seeking Alpha - Wed Feb 11, 2:26PM CST
BIIB: 391.66 (-0.45)
Isis Pharma to Get $5M from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 1:42PM CST
Isis Pharmaceuticals (ISIS) to receive a milestone payment of $5 million from Biogen (BIIB).
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ISIS: 63.86 (-0.43)
Why Sangamo Biosciences Inc. Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 11, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Sangamo Biosciences shares surged more than 14%...
BIIB: 391.66 (-0.45), SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
Stocks Open Mixed, Techs Climb; Rite Aid, Akamai, AmTrust Jump
at Investor's Business Daily - Wed Feb 11, 9:36AM CST
Stocks opened in a tightly mixed formation Wednesday, as tech stocks pulled higher and the energy sector once again turned south. The Nasdaq climbed 0.2% with a strong mix of Nasdaq 100 stocks pulling higher. The Dow Jones industrial average fell...
KO: 41.99 (-0.18), TSLA: 203.77 (+0.89), BIIB: 391.66 (-0.45), BIDU: 212.13 (+7.11), PNRA: 155.02 (-2.31), AKAM: 68.77 (+1.18), AFSI: 55.60 (-0.89), CAT: 85.13 (+1.60), CSCO: 29.43 (-0.03), RAD: 8.34 (+0.25)
Charles River (CRL) Beats on Q4 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:54AM CST
Charles River Laboratories (CRL) reported fourth-quarter 2014 earnings (excluding special items) of 81 cents per share, easily beating both the Zacks Consensus Estimate of 71 cents.
BIIB: 391.66 (-0.45), ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CRL: 73.61 (-0.33)
Isis Pharmaceuticals announces USD5m milestone payment from Biogen Idec
M2 - Wed Feb 11, 5:08AM CST
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Tuesday that it has earned a USD5m milestone payment with respect to a neurological disorder programme partnership from Biogen Idec.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:30PM CST
Orexigen Therapeutics (OREX) announced encouraging updates on its weight loss drug, Mysimba
BIIB: 391.66 (-0.45), OREX: 5.55 (+0.10), ALNY: 95.54 (+1.67)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 391.66 (-0.45), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13), ALKS: 71.40 (-1.89)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:26AM CST
Acorda Therapeutics's (ACOR) fourth quarter earnings of 33 cents per share surpassed the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ACHN: 10.89 (-0.20), ACOR: 36.14 (-0.51)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
1 Sentence That Tells You Everything You Need to Know About Each of These 10 Big Pharma Earnings Rep
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 13, 7:02AM CST
Source: AstraZeneca. Earnings season is more than halfway over, and it hasn't been easy to keep pace with hundreds upon hundreds of earnings reports, sometimes all hitting within the same day. Much of the healthcare sector, especially big...
BIIB: 391.66 (-0.45), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16)
Sucampo, Par Pharmaceuticals Enter License Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:23PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) announced that the company and its partner R-Tech Ueno, Ltd have entered into a stipulation and license agreement with Par Pharmaceutical, Inc.
IPXL: 39.51 (+0.69), LCI: 57.78 (-0.91), BIIB: 391.66 (-0.45), SCMP: 15.32 (+0.04)
Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 11:40AM CST
Oncolytics Biotech Inc.'s (ONCY) lead candidate, Reolysin, has been granted orphan drug designation by the FDA for the treatment of ovarian cancer.
BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), BMRN: 100.76 (+1.98)
Forget Gilead Sciences: Here Are 3 Better Biotech Stocks
Motley Fool Staff - Motley Fool - Thu Feb 12, 7:19AM CST
A doubling of Gilead Sciences ' sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences' sales growth set to slow this year, investors may find that these three top biotech stocks...
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 1.30% Loss
Comtex SmarTrend(R) - Wed Feb 11, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $388.53 to a high of $396.86. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $394.06 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 391.66 (-0.45)
Stocks End Mixed: Molina Healthcare Rises Again
at Investor's Business Daily - Wed Feb 11, 3:22PM CST
Stocks ended mixed Wednesday as investors fretted about talks between Greek and European finance ministers about a debt compromise. The Nasdaq edged up 0.3%, while the S&P 500 and the Dow Jones industrial average each dipped a fraction. Volume was...
BIIB: 391.66 (-0.45), MOH: 59.66 (+0.26), CELG: 115.88 (+0.16), RAD: 8.34 (+0.25)
Biogen Idec: A True Competitor On Sustainability Metrics
Katherine Schrank - at Seeking Alpha - Wed Feb 11, 2:26PM CST
BIIB: 391.66 (-0.45)
Isis Pharma to Get $5M from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 1:42PM CST
Isis Pharmaceuticals (ISIS) to receive a milestone payment of $5 million from Biogen (BIIB).
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), BMRN: 100.76 (+1.98), ISIS: 63.86 (-0.43)
Why Sangamo Biosciences Inc. Shares Rocketed Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 11, 11:58AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Sangamo Biosciences shares surged more than 14%...
BIIB: 391.66 (-0.45), SHPG: 239.82 (+6.11), SGMO: 15.40 (+0.14)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
Stocks Open Mixed, Techs Climb; Rite Aid, Akamai, AmTrust Jump
at Investor's Business Daily - Wed Feb 11, 9:36AM CST
Stocks opened in a tightly mixed formation Wednesday, as tech stocks pulled higher and the energy sector once again turned south. The Nasdaq climbed 0.2% with a strong mix of Nasdaq 100 stocks pulling higher. The Dow Jones industrial average fell...
KO: 41.99 (-0.18), TSLA: 203.77 (+0.89), BIIB: 391.66 (-0.45), BIDU: 212.13 (+7.11), PNRA: 155.02 (-2.31), AKAM: 68.77 (+1.18), AFSI: 55.60 (-0.89), CAT: 85.13 (+1.60), CSCO: 29.43 (-0.03), RAD: 8.34 (+0.25)
Charles River (CRL) Beats on Q4 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 8:54AM CST
Charles River Laboratories (CRL) reported fourth-quarter 2014 earnings (excluding special items) of 81 cents per share, easily beating both the Zacks Consensus Estimate of 71 cents.
BIIB: 391.66 (-0.45), ABC: 100.34 (+0.51), MCK: 224.89 (+0.12), CRL: 73.61 (-0.33)
Isis Pharmaceuticals announces USD5m milestone payment from Biogen Idec
M2 - Wed Feb 11, 5:08AM CST
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Tuesday that it has earned a USD5m milestone payment with respect to a neurological disorder programme partnership from Biogen Idec.
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43)
Jim Cramer's 'Mad Money' Recap: No Foreign News Is Great U.S. News
at The Street - Tue Feb 10, 7:35PM CST
With no distractions, the U.S stock market rallied on a slew of terrific company news.
BIIB: 391.66 (-0.45), UNH: 109.44 (-0.40), SYY: 39.54 (-0.12), HOT: 78.55 (+0.67), HUM: 152.67 (-1.06), SBUX: 91.58 (-0.24), SAVE: 79.32 (-0.80), MAT: 27.61 (+0.17), CMG: 674.89 (+4.60), TASR: 26.96 (-0.42), REGN: 402.40 (+0.66), SIRI: 3.83 (-0.07), KO: 41.99 (-0.18), HAS: 62.74 (+0.58), DIS: 104.17 (+0.59), ALKS: 71.40 (-1.89), MAS: 26.45 (+0.02), ARO: 3.63 (+0.04), CELG: 115.88 (+0.16), URBN: 38.47 (+0.27), BAX: 70.39 (+0.31), ACHN: 10.89 (-0.20), GM: 37.62 (-0.40), YELP: 47.53 (-0.10), HMSY: 20.00 (+0.38)
Orexigen Gives Positive Updates on its Weight Loss Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:30PM CST
Orexigen Therapeutics (OREX) announced encouraging updates on its weight loss drug, Mysimba
BIIB: 391.66 (-0.45), OREX: 5.55 (+0.10), ALNY: 95.54 (+1.67)
Alkermes Reports Positive Data on Multiple Sclerosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 3:20PM CST
Alkermes (ALKS) reported positive top-line data from an early-stage study on its experimental multiple sclerosis treatment, ALKS 8700.
BIIB: 391.66 (-0.45), OPHT: 51.11 (+0.12), PRTA: 22.89 (+0.13), ALKS: 71.40 (-1.89)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
